Aligning approaches to rheumatoid arthritis drug development: a comparison of FDA and EMA guidance.

Ciancio A, Amati A, Gandolfo S, Grieshaber-Bouyer R, Thomas R, Liew DFL, Valenzuela G, Gossec L, Manara M, Kim TH, Szekanecz Z, Taylor PC, Mariette X, Caporali R, Ciccia F

Open source

DOI: 10.1016/s2665-9913(26)00086-x
Published: 2026 Jul
Container: The Lancet. Rheumatology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2665-9913-26-00086-x,
  title = {Aligning approaches to rheumatoid arthritis drug development: a comparison of FDA and EMA guidance.},
  author = {Ciancio A and Amati A and Gandolfo S and Grieshaber-Bouyer R and Thomas R and Liew DFL and Valenzuela G and Gossec L and Manara M and Kim TH and Szekanecz Z and Taylor PC and Mariette X and Caporali R and Ciccia F},
  year = {2026},
  journal = {The Lancet. Rheumatology},
  doi = {10.1016/s2665-9913(26)00086-x},
  url = {https://doi.org/10.1016/s2665-9913(26)00086-x}
}

RIS

TY  - JOUR
TI  - Aligning approaches to rheumatoid arthritis drug development: a comparison of FDA and EMA guidance.
AU  - Ciancio A
AU  - Amati A
AU  - Gandolfo S
AU  - Grieshaber-Bouyer R
AU  - Thomas R
AU  - Liew DFL
AU  - Valenzuela G
AU  - Gossec L
AU  - Manara M
AU  - Kim TH
AU  - Szekanecz Z
AU  - Taylor PC
AU  - Mariette X
AU  - Caporali R
AU  - Ciccia F
PY  - 2026
JO  - The Lancet. Rheumatology
DO  - 10.1016/s2665-9913(26)00086-x
UR  - https://doi.org/10.1016/s2665-9913(26)00086-x
ER  -

APA

A, C., A, A., S, G., R, G., R, T., DFL, L., G, V., L, G., M, M., TH, K., Z, S., PC, T., X, M., R, C., & F, C. (2026). Aligning approaches to rheumatoid arthritis drug development: a comparison of FDA and EMA guidance.. The Lancet. Rheumatology. https://doi.org/10.1016/s2665-9913(26)00086-x

Source records

pubmed · retrieved 2026-09-26T21:05:00.168Z